New drug may boost recovery in kids with rare bone marrow failure

NCT ID NCT06430788

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving emapalumab early can help children with newly diagnosed severe aplastic anemia recover their blood cell counts within 6 weeks. About 35 children will receive the drug before standard treatments. The goal is to see if this approach improves treatment planning and outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia Bone Marrow Failure Disorders Cytopenia pancytopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA CYTOPENIA HYPOCELLULAR MARROW

Contacts and locations

Locations

Children's Hospital of Philadelphia (Data Collection AND Specimen Analysis)
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Children's Hospital of Wisconsin (Data Collection Only)
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Cincinnati Children's Hospital Medical Center (Data collection only)
RECRUITING

Cincinnati, Ohio, 45229, United States
Medical College of Wisconsin (Data Collection AND Data Analysis)
NOT_YET_RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING

New York, New York, 10065, United States
Virginia Commonwealth University (Data Collection Only )
RECRUITING

Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.